What is the share price of Remedium Lifecare Ltd (REMLIFE) today?
The share price of REMLIFE as on 7th March 2025 is ₹2.52. The stock prices are volatile and keep changing through the day depending upon various factors and market conditions.What is the return on Remedium Lifecare Ltd (REMLIFE) share?
The past returns of Remedium Lifecare Ltd (REMLIFE) share are- Past 1 week: -9.77%
- Past 1 month: -40.15%
- Past 3 months: -55.00%
- Past 6 months: -74.88%
- Past 1 year: -91.91%
- Past 3 years: 104.15%
- Past 5 years: 1228.19%
What are the peers or stocks similar to Remedium Lifecare Ltd (REMLIFE)?
The peers or stocks similar to Remedium Lifecare Ltd (REMLIFE) include:What is the market cap of Remedium Lifecare Ltd (REMLIFE) share?
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Remedium Lifecare Ltd (REMLIFE) is ₹101.61 Cr as of 7th March 2025.What is the 52 week high and low of Remedium Lifecare Ltd (REMLIFE) share?
The 52-week high of Remedium Lifecare Ltd (REMLIFE) is ₹33.25 and the 52-week low is ₹2.18.What is the PE and PB ratio of Remedium Lifecare Ltd (REMLIFE) stock?
The P/E (price-to-earnings) ratio of Remedium Lifecare Ltd (REMLIFE) is 3.10. The P/B (price-to-book) ratio is 2.37.Which sector does Remedium Lifecare Ltd (REMLIFE) belong to?
Remedium Lifecare Ltd (REMLIFE) belongs to the Health Care sector & Pharmaceuticals sub-sector.How to buy Remedium Lifecare Ltd (REMLIFE) shares?
You can directly buy Remedium Lifecare Ltd (REMLIFE) shares on Tickertape. Simply sign up, connect your demat account and place your order.
Remedium Lifecare Ltd
REMLIFERemedium Lifecare Ltd
REMLIFE
Health CarePharmaceuticals
SmallcapWith a market cap of ₹101 cr, stock is ranked 2,941
High RiskStock is 4.45x as volatile as Nifty
2.525.00% (+0.12)
2.525.00% (+0.12)
Price Chart
High
—
Low
—
Returns
—
1D
1W
1M
1Y
5Y
Max
SIP
1D
1W
1M
1Y
5Y
Max
SIP
How to use scorecard? Learn more
Key Metrics
| No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
|---|---|---|
| -2.05 | 2.37 | — |
| Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
|---|---|---|
| 47.25 | 6.02 | 0.55% |
Forecast & Ratings
Detailed Forecast —
Forecast data is currently unavailable for this stockPrice
Price Upside
Earnings
Earnings Growth
Revenue
Rev. Growth
Company Profile
Remedium Lifecare Ltd is a pharmaceutical company engaged in trading and manufacturing active pharmaceutical ingredients (APIs) and intermediates for domestic and international markets, including regulated markets.
Peers
Compare with peersSUNPHARMA
PE Ratio
40.32
1Y Return
0.22%
Buy Reco %
85.29
CIPLA
PE Ratio
28.58
1Y Return
1.67%
Buy Reco %
72.73
TORNTPHARM
PE Ratio
62.81
1Y Return
15.35%
Buy Reco %
68.00
MANKIND
PE Ratio
49.95
1Y Return
7.51%
Buy Reco %
80.00
DRREDDY
PE Ratio
16.93
1Y Return
10.40%
Buy Reco %
45.16
Get more out of Tickertape, Go Pro!
Customise key metrics, see detailed forecasts, download stock data and more
Forecasts
Price
Revenue
Earnings
Price Forecast
Hmm, looks like data is unavailable here. Please come back after some timeRevenue Forecast
Hmm, looks like data is unavailable here. Please come back after some timeEarnings Per Share Forecast
Hmm, looks like data is unavailable here. Please come back after some timeIncome
Balance Sheet
Cash Flow
Annual Normal View
Income Statement
Annual Normal View
| Financial Year | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | TTM | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 4.26 | 1.43 | 0.37 | 0.25 | 2.89 | 90.03 | 504.79 | 509.84 | 4,062.79 | 1,562.46 | ||||||||||
Raw Materials | 3.65 | 0.71 | 0.14 | 0.00 | 0.00 | 0.00 | 0.00 | 417.30 | 4,127.29 | 1,585.08 | ||||||||||
| Power & Fuel Cost | 0.08 | 0.08 | 0.02 | 0.00 | 0.05 | 0.07 | 0.09 | 0.06 | 0.06 | |||||||||||
| Employee Cost | 0.05 | 0.04 | 0.13 | 0.04 | 0.18 | 0.19 | 0.21 | 0.55 | 0.40 | |||||||||||
| Selling & Administrative Expenses | 0.20 | 0.13 | 0.05 | 0.00 | 0.47 | 1.09 | 3.76 | 6.46 | 4.95 | |||||||||||
| Operating & Other expenses | 0.25 | 0.47 | 0.01 | 0.19 | 1.79 | 87.96 | 498.91 | 77.46 | -125.20 | |||||||||||
EBITDA | 0.03 | 0.00 | 0.02 | 0.02 | 0.40 | 0.72 | 1.82 | 8.01 | 55.29 | -22.62 | ||||||||||
| Depreciation/Amortization | 0.01 | 0.00 | 0.00 | 0.00 | 0.01 | 0.06 | 0.07 | 0.15 | 0.06 | 0.04 | ||||||||||
| PBIT | 0.02 | 0.00 | 0.02 | 0.02 | 0.39 | 0.66 | 1.75 | 7.86 | 55.23 | -22.66 | ||||||||||
| Interest & Other Items | 0.01 | 0.00 | 0.00 | 0.00 | 0.01 | 0.02 | 0.23 | 0.45 | 4.78 | 7.54 | ||||||||||
| PBT | 0.01 | 0.00 | 0.02 | 0.02 | 0.38 | 0.64 | 1.52 | 7.41 | 50.45 | -30.20 | ||||||||||
| Taxes & Other Items | 0.00 | 0.00 | 0.00 | 0.02 | 0.09 | 0.17 | 0.45 | 1.97 | 17.72 | 19.32 | ||||||||||
| Net Income | 0.01 | 0.00 | 0.02 | -0.00 | 0.29 | 0.47 | 1.07 | 5.44 | 32.73 | -49.52 | ||||||||||
| EPS | 0.00 | 0.00 | 0.00 | -0.00 | 0.01 | 0.01 | 0.03 | 0.13 | 1.48 | -12.28 | ||||||||||
| DPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||||||
| Payout ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Company Updates
FY 2016
Annual report
PDFFY 2017
Annual report
PDFFY 2018
Annual report
PDFFY 2019
Annual report
PDFFY 2020
Annual report
PDFFY 2021
Annual report
PDFFY 2022
Annual report
PDFFY 2023
Annual report
PDFFY 2024
Annual report
PDFPeers & Comparison
Comparing 3 stocks from
Health CarePharmaceuticals
Compare valuation on Screener
Health CarePharmaceuticals
Valuation
Technical
Forecast
Compare valuation on Screener| Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
|---|---|---|---|
| Remedium Lifecare Ltd | 3.10 | 2.37 | — |
| Sun Pharmaceutical Industries Ltd | 40.32 | 5.75 | 0.84% |
| Cipla Ltd | 28.58 | 4.39 | 0.89% |
| Torrent Pharmaceuticals Ltd | 62.81 | 15.17 | 0.91% |
Price Comparison
Compare REMLIFE with any stock or ETFCompare REMLIFE with any stock or ETF
REMLIFE
Shareholdings
Promoter Holdings Trend
Total Promoter Holding
Increasing promoter holding is considered good and reflects management’s positive view about the future outlook
In last 6 months, promoter holding in the company has almost stayed constant
Low Pledged Promoter Holding
Lower pledged promoter holdings is considered better
Pledged promoter holdings is insignificant
Institutional Holdings Trend
Increased Total Retail Holding
Increasing retail holding can be considered bad as it can reflect that institutions and promoters are selling their stake which is being absorbed by retail investors.
In last 3 months, retail holding in the company has increased by 4.73%
Foreign Institutional Holding
Foreign Institutional Holding is quantum of stock held by foreign large-quantities-trading entities. Increasing value indicates growing support and comfort for the stock
In last 3 months, foreign institutional holding of the company has almost stayed constant
Shareholding Pattern
Shareholding History
Foreign Institutions
smallcases
Looks like this stock is not in any smallcase yet.
Events
Dividend Trend
No Dividends
Dividends are the portion of earnings that a company distributes to all its shareholders every year
REMLIFE has not given any dividends in last 5 years
Dividends
Corp. Actions
Announcements
Legal Orders
Dividends
Dividends
Hmm, looks like data is unavailable here. Please come back after some timeNews & Opinions
Articles & Videos
Earnings
Remedium Lifecare standalone net profit declines 98.34% in the December 2024 quarter
Net profit of Remedium Lifecare declined 98.34% to Rs 0.76 crore in the quarter ended December 2024 as against Rs 45.82 crore during the previous quarter ended December 2023. Sales declined 97.92% to Rs 38.15 crore in the quarter ended December 2024 as against Rs 1834.18 crore during the previous quarter ended December 2023. ParticularsQuarter EndedDec. 2024Dec. 2023% Var. Sales38.151834.18 -98 OPM %-14.392.98 - PBDT1.0668.79 -98 PBT1.0568.78 -98 NP0.7645.82 -98 Powered by Capital Market - Live
3 weeks agoCapital Market - Live
Corporate
Remedium Lifecare to convene board meeting
Remedium Lifecare will hold a meeting of the Board of Directors of the Company on 14 February 2025.Powered by Capital Market - Live
3 weeks agoCapital Market - Live
Corporate
Remedium Lifecare to convene board meeting
Remedium Lifecare will hold a meeting of the Board of Directors of the Company on 22 January 2025.Powered by Capital Market - Live
1 month agoCapital Market - Live
Earnings
Remedium Lifecare standalone net profit declines 72.74% in the September 2024 quarter
Net profit of Remedium Lifecare declined 72.74% to Rs 1.78 crore in the quarter ended September 2024 as against Rs 6.53 crore during the previous quarter ended September 2023. Sales declined 94.65% to Rs 25.08 crore in the quarter ended September 2024 as against Rs 468.57 crore during the previous quarter ended September 2023. ParticularsQuarter EndedSep. 2024Sep. 2023% Var. Sales25.08468.57 -95 OPM %17.781.35 - PBDT2.4710.42 -76 PBT2.4610.41 -76 NP1.786.53 -73 Powered by Capital Market - Live
3 months agoCapital Market - Live
Corporate
Remedium Lifecare to declare Quarterly Result
Remedium Lifecare will hold a meeting of the Board of Directors of the Company on 14 November 2024Powered by Capital Market - Live
3 months agoCapital Market - Live
Corporate
Remedium Lifecare postpones board meeting
Remedium Lifecare has postponed the meeting of the Board of Directors which was scheduled to be held on 3 September 2024. The meeting will now be held on 4 September 2024.Powered by Capital Market - Live
6 months agoCapital Market - Live
Corporate
Remedium Lifecare to convene board meeting
Remedium Lifecare will hold a meeting of the Board of Directors of the Company on 3 September 2024.Powered by Capital Market - Live
6 months agoCapital Market - Live
Earnings
Remedium Lifecare standalone net profit declines 68.76% in the June 2024 quarter
Net profit of Remedium Lifecare declined 68.76% to Rs 1.64 crore in the quarter ended June 2024 as against Rs 5.25 crore during the previous quarter ended June 2023. Sales declined 76.49% to Rs 77.70 crore in the quarter ended June 2024 as against Rs 330.46 crore during the previous quarter ended June 2023. ParticularsQuarter EndedJun. 2024Jun. 2023% Var. Sales77.70330.46 -76 OPM %0.502.20 - PBDT2.287.28 -69 PBT2.277.27 -69 NP1.645.25 -69 Powered by Capital Market - Live
6 months agoCapital Market - Live
Corporate
Remedium Lifecare postpones board meeting
Remedium Lifecare has postponed the meeting of the Board of Directors which was scheduled to be held on 8 August 2024. The meeting will now be held on 14 August 2024.Powered by Capital Market - Live
6 months agoCapital Market - Live
Corporate
Remedium Lifecare to acquire technology for manufacturing lithium carbonate in India
Remedium Lifecare has entered into a strategic agreement with Angel Partners, UK, effective 29 July 2024, to acquire technology for manufacturing lithium carbonate in India. The company has also signed an annual Supply Agreement with Alfa Chemicals and Solvents, Turkey, effective the same date. Supplies of technical-grade lithium carbonate will commence in the January-March 2025 quarter. The supplies for CY 2025 are valued at USD 20-25 million. Technical-grade lithium carbonate is used in lithium-ion batteries for electric vehicles and portable electronics. Remedium has partnered with various contract manufacturers to produce technical-grade lithium carbonate using the technology from Angel Partners. Powered by Capital Market - Live
7 months agoCapital Market - Live
Higher than Industry Revenue Growth
Over the last 5 years, revenue has grown at a yearly rate of 595.31%, vs industry avg of 9.04%
Increasing Market Share
Over the last 5 years, market share increased from 0% to 1.07%